Importance An increased risk of lymphoma has been reported among patients receiving
thiopurines for inflammatory bowel disease (IBD). The risk of lymphoma associated with anti …

OBJECTIVES: The objective of this study was to assess inflammatory bowel disease (IBD)
medications in relation to lymphoma risk. METHODS: Information on IBD and relevant …

Background The risk of lymphoma in patients with inflammatory bowel disease (IBD) treated
with anti‐TNF agents remains unclear. Aim To assess the comparative risk of lymphoma with …

Purpose We aimed to analyse malignancy rates and predictors for the development of
malignancies in a large German inflammatory bowel disease (IBD) cohort treated with …

Background Reports of an increased risk of lymphoproliferative disorders in patients
receiving thiopurines for inflammatory bowel disease are controversial. We assessed this …

Background & Aims Thiopurine therapy for inflammatory bowel disease (IBD) has been
associated with increased risk for lymphoma. We estimated the relative risk of lymphoma in …

Background & Aims The risk of infection associated with tumor necrosis factor antagonists
(anti-TNF) and thiopurines (combination therapy) is uncertain. We assessed the risk of …

Aliment Pharmacol Ther 2010; 32: 119–130 Summary Background Immunosuppression is a
risk factor for carcinogenesis. Thiopurines specifically contribute to this. As thiopurines are …

Background & Aims There is controversy over whether the treatment of patients with
ulcerative colitis (UC) with thiopurines increases their risk of lymphoma. We evaluated the …

Background & Aims Treatment with immunosuppressive thiopurines such as azathioprine is
associated with an increased risk of leukemogenesis. We assessed the risk of myeloid …